Tagrisso (Osimertinib Mesylate) Patent Expiration, LOE Window & CMS Spending
Tagrisso (Osimertinib Mesylate) by AstraZeneca: FDA Orange Book core substance LOE 2032-08-08 (last listed 2042-11-26), 0 AB generics, $1.80B 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AstraZeneca |
| FDA Application & Pathway | N208065 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2032-08-08 |
| Last Listed Patent or Exclusivity Date | 2042-11-26 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.80B |
| 2024 Medicare Part D Spend | $1.63B |
| 2024 Medicaid Spend | $174.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.